JIP
MYGN icon

Jaffetilchin Investment Partners’s Myriad Genetics MYGN Stock Holding History

Jaffetilchin Investment Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42,807
Closed -$227K – 455
2025
Q2 		$227K Buy
+42,807
New +$253K 0.01% 388

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jaffetilchin Investment Partners's MYGN Position: Q3 2025 in Review

Jaffetilchin Investment Partners sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 42,807 shares — an estimated $227K sold.

Jaffetilchin Investment Partners first reported a position in MYGN in Q2 2025 and held it in 1 quarter. The position peaked at $227K in Q2 2025. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Jaffetilchin Investment Partners reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 42,807 Myriad Genetics shares in Q3 2025, an estimated $227K.
  • Jaffetilchin Investment Partners first reported a position in Myriad Genetics in Q2 2025 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Myriad Genetics position peaked at $227K in Q2 2025.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Jaffetilchin Investment Partners's 13F filing for Q3 2025, filed 13 Nov 2025.